TB-500
Recovery discussions where the exact peptide identity matters.
The short version
- Why people discuss it
- Discussed alongside BPC-157 for muscle, tendon and ligament recovery. Those community claims are broader than the human evidence collected here.
- What it is
- TB-500 is used inconsistently in product and community language. Full-length thymosin beta-4 and its short fragment are different substances; a name alone does not identify a vial.
- Biggest caution
- FDA reports no identified human exposure data for drug products containing the thymosin beta-4 fragment. Full-length eye-drop research cannot establish safety for a differently identified injection.
- Stack context
- Discussed with BPC-157 and in KLOW. The small BPC-157/TB4 subgroup does not show that combining them works better.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Subcutaneous injection; product identity varies
Community reference · Not clinical guidance- Amount
- 1–1.5 mg per administration
- Frequency
- Twice weekly during loading
- Duration / phase
- 4–6 weeks
Peptidepedia loading example. Older sources report 2–2.5 mg twice weekly; PeptideDosages instead gives 0.5–1 mg daily for 8–12 weeks. Similar weekly totals do not make these schedules equivalent; exact TB-500 identity remains uncertain. Reference only; this does not establish safety, effectiveness or individual suitability.
Community source · reviewed 2026-09-27Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
Standalone 0.5–1 mg SC daily for 8–12 weeks; separate-vial stack instead 1.25 mg twice/week then weekly.
- Peptidepedia — saved source reviewed September 27, 2026
1–1.5 mg SC/IM twice/week for 4–6 weeks; maintenance 1–2 mg weekly.
Evidence & sources · Identity-dependent evidence
Community references document claims and reported practices. They are not clinical evidence. Some references contain supplier promotions or market treatment; their commercial context is identified in the source label.
- Preferred Regen: four-peptide stack discussion (clinic marketing)Community reference · Checked 2026-09-12
- FDA: peptide compounding safety concernsRegulatory source · Checked 2026-09-12
- BPC-157 plus TB4 subgroupExisting research · Checked 2026-09-08
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27
- Peptidepedia — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27